Acumen Pharmaceuticals, Inc. ABOS
Institutional shares held
41.8 Million
57.7K
calls
749K
puts
Total value of holdings
$100M
$137K
calls
$1.79M
puts
Market Cap
$96.8M
40,503,100
Shares Out.
Institutional ownership
103.28%
# of Institutions
78
We take great care to ensure that the data presented and summarized in this overview for Acumen Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABOS
View all-
Ra Capital Management, L.P. Boston, MA14.9MShares$35.7 Million0.52% of portfolio
-
Franklin Resources Inc San Mateo, CA3.55MShares$8.48 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$8.17 Million4.37% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.5 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$5.16 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.93MShares$4.62 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.83MShares$4.39 Million0.0% of portfolio
-
Knollwood Investment Advisory, LLC Hunt Valley, MD1.63MShares$3.89 Million0.43% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL940KShares$2.25 Million0.01% of portfolio
-
Laurion Capital Management LP New York, NY867KShares$2.07 Million0.03% of portfolio
Latest Institutional Activity in ABOS
Top Purchases
Top Sells
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Transactions at ABOS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 19
2024
|
Derek M Meisner Chief Legal Officer & Corp Sec |
SELL
Open market or private sale
|
Direct |
8,933
-7.58%
|
$26,799
$3.48 P/Share
|
|
Jan 19
2024
|
Daniel Joseph O Connell President and CEO |
SELL
Open market or private sale
|
Direct |
15,200
-2.94%
|
$45,600
$3.47 P/Share
|
|
Jan 18
2024
|
Eric Siemers Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,124
-2.59%
|
$9,372
$3.71 P/Share
|
|
Jan 18
2024
|
Matt Zuga CFO & Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,242
-1.97%
|
$12,726
$3.7 P/Share
|
|
Jan 18
2024
|
Russell Barton Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,833
-2.84%
|
$8,499
$3.73 P/Share
|
|
Jan 02
2024
|
Matt Zuga CFO & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
106,000
+32.95%
|
-
|
|
Jan 02
2024
|
Eric Siemers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,000
+43.78%
|
-
|
|
Jan 02
2024
|
Derek M Meisner Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
91,000
+43.58%
|
-
|
|
Jan 02
2024
|
Russell Barton Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,000
+42.27%
|
-
|
|
Jan 02
2024
|
Daniel Joseph O Connell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
401,000
+43.65%
|
-
|
|
Aug 17
2023
|
Jeffrey L. Ives Director |
SELL
Open market or private sale
|
Direct |
41,949
-100.0%
|
$251,694
$6.57 P/Share
|
|
Aug 17
2023
|
Jeffrey L. Ives Director |
BUY
Exercise of conversion of derivative security
|
Direct |
41,949
+50.0%
|
$0
$0.96 P/Share
|
|
Jul 21
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,161,290
+28.35%
|
$36,129,030
$7.75 P/Share
|
|
Jan 17
2023
|
Matt Zuga CFO & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,500
+23.4%
|
-
|
|
Jan 17
2023
|
Derek M Meisner Chief Legal Officer & Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
26,800
+50.0%
|
-
|
|
Jan 17
2023
|
Daniel Joseph O Connell President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
114,000
+49.42%
|
-
|
|
Jan 17
2023
|
Eric Siemers Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+50.0%
|
-
|
|
Jan 17
2023
|
Russell Barton Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+50.0%
|
-
|
|
Dec 29
2022
|
Matt Zuga CFO & Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+39.62%
|
$50,000
$1.19 P/Share
|
|
Nov 30
2021
|
Daniel Joseph O Connell President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,118
+29.4%
|
$4,472
$4.47 P/Share
|
Last 12 Months Summary
Buy / Acquisition
765K
Shares
From
5
Insiders
| Grant, award, or other acquisition | 765K shares |
|---|
Sell / Disposition
34.3K
Shares
From
5
Insiders
| Open market or private sale | 34.3K shares |
|---|